The HIV-Associated Diarrhea Therapeutics Market is Forecast to Show Significant Growth Until 2019

Tuesday 13 March 2012, Amsterdam

The industry analysis specialist, has released its new report, “HIV-Associated Diarrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Human Immunodeficiency Virus (HIV) associated diarrhea therapeutics market. The report identifies the key trends shaping and driving the global HIV-associated diarrhea therapeutics market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on pipeline products within the global HIV-associated diarrhea therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.


The HIV-Associated Diarrhea Therapeutics Market is Forecast to Show Significant Growth Until 2019

An analysis suggests that the global Human Immunodeficiency Virus (HIV)-associated diarrhea therapeutics market was worth $499.1m in 2011. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.2% over the next eight years, to reach $935.5m by 2019. The global HIV-associated diarrhea therapeutics market will be driven by the launch of a new and efficacious treatment option which is in the late stage of development. The growth will be further augmented by the increasing incidence and associated factors.


HIV-Associated Diarrhea Therapeutics Market has Weak Competition between Few Generics

They analyzed the current competitive landscape for HIV-associated diarrhea drugs and found the competition to be weak. The HIV-associated diarrhea therapeutics market consists of antiprotozoal and anti-diarrheal drugs. Competition in the HIV-associated diarrhea therapeutics market is driven not only by product characteristics such as their efficacy and safety profile, but also by market characteristics such as the number of competitors, pricing and generics. The HIV-associated diarrhea therapeutics market is dominated by generic products which have medium to high efficacy and safety profiles. The current market does not contain any branded products. There is weak competition among the generic products. Another disadvantage associated with most of the current anti-diarrheal products is that they are absorbed into the blood and distributed throughout the body. This increases the risk of drug interaction with other drugs. These anti-diarrheal drugs slow down the flow of material through the intestine. This stops diarrhea but also increases the amount of time the toxin remains in the intestines, increasing the risk of infection for the patient. The risk is higher in HIV patients. The strong pipeline product will dominate the HIV-associated diarrhea therapeutics market in the future.


HIV-Associated Diarrhea Therapeutics Market has Significant Unmet Need

They found that the global HIV-associated diarrhea therapeutics market holds potential as the unmet need is significant. Currently there are pathogen specific and symptomatic treatments available for HIV-associated diarrhea, mostly constituted by generic drugs. These drugs have medium efficacy and safety profiles. The disadvantage of the current anti-diarrheal drugs is that they are absorbed into the blood and distributed throughout the body. This increases the risk of the drugs interacting with other drugs. These anti-diarrheal drugs also slow down the flow of material through the intestine, which raises the duration of intestinal toxin on the material and infect the host. This risk of these side effects is higher in HIV patients. Furthermore, there is no marketed anti-diarrheal drug approved specifically for HIV patients. This implies that new targeted therapies with improved efficacy and safety profiles are required. Significant opportunities lie in improvements upon existing products. An efficacious product with a high safety profile will have the potential to capture a significant share of the market.


Strong Clinical Pipeline has Molecule with Improved Efficacy and Safety Profiles and Added Advantage over Current Prescribed Drugs

They analyzed the HIV-associated diarrhea pipeline and found it to be strong. However, the pipeline consists of only two molecules in Phase III and Phase II of clinical development. Of these, Crofelemer is a late stage pipeline product with a novel Mechanism Of Action (MOA) and unique spectrum of activity. Crofelemer is in the late stage of development and has fast track designation by the US Food and Drug Administration (FDA).

The late stage pipeline product can match or exceed the efficacy and safety of the currently marketed products in terms of significantly reducing stool weight, frequency and chloride concentration. No serious side effects were observed in the patients in the clinical trial and the drug was well tolerated. This implies that patients and physicians will have better treatment options in the near future. A strong clinical pipeline coupled with moderate unmet need in the HIV-associated diarrhea therapeutics market is expected to drive market growth during the forecast period.